Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (532)	4/26/2006 9:07:47 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Patent Awarded for Production of Introgen's ADVEXIN Therapy; Patent Broadly Covers All Adenoviral p53 Manufacturing Methods Wednesday April 26, 2:00 pm ET AUSTIN, Texas, April 26 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) announced today that a patent has been awarded by the U.S. Patent and Trademark Office which broadly covers methods used to produce adenoviral p53, thus expanding Introgen's adenoviral p53 portfolio and protection for its lead cancer therapy, ADVEXIN. The patent, U.S. Patent No. 7,033,750, is one of numerous patents, pending or issued, that Introgen has licensed exclusively from the Board of Regents of The University of Texas System which cover its therapies. Introgen's ADVEXIN therapy uses non-replicating adenovirus, a very important and frequently used tool in the fields of tumor suppressor therapy and vaccines. In addition to Introgen's product candidates ADVEXIN, INGN 241, INGN 225, INGN 224 and INGN 007, there are a number of purified adenoviral products being developed worldwide. "This patent adds considerably to Introgen's extensive adenovirus intellectual property portfolio," said David L. Parker, J.D., Ph.D., vice president of Intellectual Property for Introgen. "This patent is of particular importance in that it is directed to the production of adenoviral p53 in producer cells, and complements our existing U.S. portfolio, which includes patents directed to pharmaceutical compositions of adenoviral p53, the adenoviral p53 itself and to clinical applications of adenoviral p53." Introgen holds a license agreement with The University of Texas M. D. Anderson Cancer Center to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M.D. Anderson's conflict of interest policies.